OS Therapies forms subsidiary OS Drug Conjugates and initiates review of strategic options for its tunable ADC & drug conjugates platforms

CAR-T Digest - August 2020

Weekly Digest - February 2025

24 Feb 2025: OS Therapies forms subsidiary OS Drug Conjugates and initiates review of strategic options for its tunable ADC & drug conjugates platforms

OS Therapies has launched a subsidiary, OS Drug Conjugates, to explore strategic initiatives for its tunable ADC (tADC) and tunable drug conjugate (tDC) platforms
The company is in discussions with clinical-stage ADC companies in the U.S., China, and other regions to form joint ventures combining their assets with OS tADC/tDC platforms, potentially leading to standalone public companies
OST-tADC and tDC offer innovative approaches for targeting various cancers, including ovarian, lung, pancreatic, osteosarcoma, breast, and esophageal cancers
OS Therapies’ tADC and tDC technologies utilize silicon-based, pH-sensitive linkers (SiLinkers) designed to release multiple therapeutic agents selectively within tumors, enhancing efficacy while minimizing toxicity to healthy cells